Seroprevalence of hepatitis B among the general population in Shandong Province, Eastern China, an update 30 years after the implementation of the neonatal vaccination program Authors: Bingyu Yan, Xiaomeng Zhang, Jingjing Lv, Yi Feng, Xin Meng, Xiaojuan Lin, Yan Zhang, Suting Wang, Feng Ji, Meng Chen, Xinyu Yuan, Zexin Tao, Li Zhang Published: 2024 ABSTRACT AbstractBackgroundIn 1992, Hepatitis B vaccine was first recommended for routine neonatal immunization in China. This study aimed to estimate the prevalence of hepatitis B virus (HBV) infection in Shandong Province, eastern China (updating our previous study in 2014), and to help guide the efforts of hepatitis B elimination.MethodsWe determined prevalence of HBV infection from the remaining serum samples collected through a population-based survey, which was originally intended for a seroepidemiological survey of anti-SARS-CoV-2 antibodies conducted in 2023. The samples (n = 5000) were obtained from individuals all-aged over 1 year residing in ten counties of Shandong Province. The chemiluminescence microparticle immunoassay was used to detect serological markers of HBV.ResultsIn total, 4999 samples were eligible for the test of hepatitis B. The overall prevalence of HBsAg, anti-HBs, and anti-HBc in the 2023 survey was 2.25% (95%CI:1.64–2.87), 46.21% (95%CI:44.05–48.38), and 25.17% (95%CI:23.46–26.88), respectively. The HBsAg prevalence has dropped to 0.28% among individuals younger than 30 years, particularly with less than 0.1% among children aged 1–14 (considerably below the 8% prevalence recorded in 1992). The peak prevalence of HBsAg was observed in individuals aged 40–49 years (5.63%), followed by those aged 30–39 (3.11%).ConclusionThe Shandong Province has achieved substantial success in controlling HBV infection among the younger generation through the newborn routine vaccination program. To accelerate progress towards the goal of eliminating hepatitis B in the province, additional strategies should also be adopted in parallel, including increasing diagnostic coverage, expanding antiviral treatment, and enhancing hepatitis B vaccine coverage for HBV-susceptible adults.Keywords: Hepatitis B, Sero-epidemiology, Prevalence, Hepatitis B vaccine, HBV elimination Introduction Hepatitis B virus (HBV) infection remains a major global public health concern. A recent model estimation revealed that approximately 257.5 million individuals worldwide were infected with HBV in 2022, with a global all-age prevalence of chronic HBV infection estimated at 3.2% [1]. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) estimated that HBV-related diseases resulted in 555 000 global deaths in 2019, accounting for 7.2% of all deaths per 100 000 people worldwide. The global prevalence of HBV infection in the general population varies considerably. According to HBsAg prevalence, countries can be roughly classified into high (≥ 8%), intermediate (2–7%), and low (< 2%) prevalence areas [2]. China used to be an area of high endemicity for hepatitis B infection in the pre-vaccination period. A national serosurvey conducted in 1992 revealed a 9.75% prevalence of hepatitis B surface antigen (HBsAg) in the general population aged 1–59 years [3]. Over the past three decades, the Chinese government has placed a significant emphasis on the timely vaccination of newborns and infants as a key strategy in the battle against hepatitis B. Hepatitis B vaccine (HepB) was first recommended for routine neonatal immunization in 1992, and was subsequently incorporated into the National Expanded Program of Immunization in 2002, with HepB provided free of charge [4–6]. During 2009–2011, a national catch-up campaign was initiated for children under the age of 15 years. In 2011, China implemented the national program for integrating prevention of mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV), syphilis, and hepatitis B, providing free hepatitis B immunoglobulin (HBIG) for children born to HBV-infected women, and it was then expanded nationwide starting in 2015 [7, 8]. Additionally, the dose of HepB has been increased from 5 µg/0.5 mL to 10 µg/0.5 mL since 2011 in order to improve the efficacy of the program. As indicated by data from national sero-epidemiological surveys, the prevalence of HBsAg among the mainland Chinese population aged 1–29 years had declined from 10.1% in 1992 to 2.6% in 2014 [9]. Currently, it is estimated that there are approximately 70 million HBsAg-positive individuals in China as of 2022 [1]. Shandong Province is situated within the eastern region of China, with an area of 156 700 km2 and a population of over 100 million (2020 census data). The data from the Shandong Center for Disease Control and Prevention (CDC) indicated that the provincial coverage of three doses of HepB for infants had exceeded 96% since 2002, as had the high coverage of timely birth-dose HepB (> 96% since 2004), and the coverage of HBIG for infants born to HBsAg-positive mothers (> 92% since 2011). A review of the results from earlier provincial surveys indicates that the HBsAg prevalence among children and adolescents aged 1–14 years had declined from 8% in 1992 to 0.21% in 2014 [10–12]. In 2016, the World Health Assembly set a target of eliminating viral hepatitis as a public health threat by 2030 [13]. Since then, the World Health Organization (WHO) has formulated a series of strategies with the aim of eliminating hepatitis B [14]. First, countries need to implement strategic information systems for the collection of surveillance and program data to effectively guide hepatitis B elimination efforts. Second, there is an urgent need to expand service coverage for testing and treatment, as well as to extend the coverage of the birth doses of HepB and to enhance the safety of healthcare injections. Third, it is essential that hepatitis services are made accessible to all members of the public, especially to health-care workers, injecting drug users, men who have sex with men, and individuals coinfected with HIV. Fourth, adequate national health funding should be provided to achieve universal health coverage, with a focus on improving the coverage of hepatitis B services, reducing the price of testing and treatment, and so on. In August 2023, the Health Commission of Shandong Province released the Three-Year Action Plan for Accelerating the Elimination of Hepatitis B Hazards in Shandong Province (2023–2025). Knowledge of a population-based sero-epidemiologic survey in an area is crucial for shaping effective preventive and control strategies for hepatitis B. The aim of this study was to provide the latest baseline data on the prevalence of HBV infection (updating our previously published data from 2014), to characterize the change in HBV epidemiology over the past decade, and to help guide the efforts of hepatitis B elimination in the province. Materials and methods Study population and sampling method We established the prevalence of HBV infection using the remaining 5000 serum specimens gathered through a population-based survey, the original intention of which was to conduct a seroepidemiological survey of anti-SARS-CoV-2 antibodies in 2023. The samples were obtained from individuals all-aged over 1 year. The 2023 survey of anti-SARS-CoV-2 antibodies was uniformly organized at the national level and approved by the China CDC Ethics Committee. The survey employed a stratified three-stage random sampling method of the national guidelines, with 10 counties in the province selected for inclusion. Subsequently, 20 villages were identified (two per county) through simple random sampling in Shandong Province. Figure 1 depicts the location of the 10 counties sampled. Furthermore, the proportion of sampled residents aged 1–2, 3–17, 18–59, and ≥ 60 years was consistent with the local natural population size. The demographic composition of the 10 sampling locations was found to be similar to that of the province as a whole (Table 1). A written informed consent was obtained from all participants, or their parents or legal guardians (if age < 18 years) prior to investigation. The remaining samples from the survey were tested for serologic indicators of hepatitis B, after which an analysis of the data was conducted. This study was approved by the Shandong CDC Ethics Committee (SDJK-2023-012-01). Location of the 10 counties investigated in 2023, Shandong Province, China Table 1Demographic composition of the population in the ten sampled locations and the whole of Shandong Province in China, 2023VariableSampled locations (%)Whole province(%)a age(year) 1–46.096.425–96.426.3510–146.046.0015–195.665.0220–245.394.5325–294.674.4130–349.049.0035–396.906.7940–446.196.2745–497.357.6650–548.759.0155–597.487.6560–645.565.7765–695.715.9770–743.703.9775–792.322.40≥ 802.732.79Chi-square = 0.35, P > 0.05 Gender Male51.0350.66Female48.9749.34Chi-square = 0.01, P > 0.05a Data source: Tabulation of the 2020 population census of Shandong province, China Demographic composition of the population in the ten sampled locations and the whole of Shandong Province in China, 2023 a Data source: Tabulation of the 2020 population census of Shandong province, China Laboratory testing With the exception of only one insufficient remaining volume of serum, 4999 (99.98%) frozen separated serum samples were eligible for the test of hepatitis B. The detection indexes included HBsAg, antibody against hepatitis B surface antigen (anti-HBs), and antibody against hepatitis B core antigen (anti-HBc), which were determined using chemiluminescence microparticle immunoassay (CMIA) on an automated ARCHITECT-i2000SR analyzer (Abbott reagent, Wiesbaden, Germany). An HBsAg level of ≥ 0.05 IU/mL, an anti-HBs level of ≥ 10 mIU/mL, and an anti-HBc level of ≥ 1 signal-to-cut-off (S/CO) were considered to indicate positivity. Statistical analysis Considering differential probabilities of selection and the complex sampling designs, we used the SAS 9.4 procedure software to calculate point estimates and 95% confidence intervals (CIs) of HBsAg, anti-HBs, and anti-HBc prevalence through the use of weighting adjustments. The demographic adjustment was based on the 2020 permanent population data of Shandong Province [15]. The Taylor series linearization method was used for the estimation of variance. The 95% CIs for the prevalence of HBsAg, anti-HBs, and anti-HBc were compared. A weighted logistic regression model was used to compare the prevalence differences between groups. Statistical significance was set at p < 0.05. The ten investigation counties were divided into three geographic areas. The eastern area included Huangdao, Laishan, Qingzhou, and Rongcheng, the middle area included Shizhong, Linzi, and Lanling, and the western area included Liangshan, Yucheng, and Mudan. The urban area included Shizhong, Huangdao, Laishan, Linzi, and Mudan, while the rural area included Qingzhou, Liangshan, Rocheng, Lanling, and Yucheng. Results Demographic characteristics In total, 4999 samples were analyzed in the 2023 survey. Overall median age was 51 [IQR, 32–63] years, with a male-to-female ratio of 0.82:1. A total of 1999 participants (39.99%) resided in urban areas and 3000 (60.01%) in rural areas. The proportion of participants living in the eastern, central, and western regions of Shandong Province was 39.98%, 30.01%, and 30.01%, respectively, and the proportion of participants by age group is shown in Table 2. Table 2Distribution of HBV serological markers by age in Shandong Province, 2023Age group(Years)TotalHBsAgAnti-HBsAnti-HBcNo.Proportion(%)Seroprevalence(%)95%CISeroprevalence(%)95%CISeroprevalence(%)95%CI1–41062.120.000.00–0.0078.5770.93–87.907.872.65–13.095–92905.800.000.00–0.0059.3851.72–67.035.202.44–7.9710–143647.280.090.00-0.2736.5029.27–43.931.520.50–2.5415–191382.760.000.00–0.0038.5320.65–50.886.752.18–11.3120–292795.580.970.00-2.1451.1145.00-57.235.062.83–7.3030–3956411.283.111.35–4.8759.8248.31–71.3323.0717.39–28.7540–4966813.365.633.03–8.2442.7838.03–47.5331.4826.89–36.0650–59114822.962.631.42–3.8338.8033.44–44.1636.8732.86–40.8860–6975415.082.731.40–4.0734.6327.62–41.6538.7430.63–46.84≥ 7068813.761.320.14–2.5036.1432.88–39.4148.2140.69–55.74Total4999100.002.251.64–2.8746.2144.05–48.3825.1723.46–26.88 Distribution of HBV serological markers by age in Shandong Province, 2023 Prevalence of HBV serological markers in 2023 Overall, the weighted prevalences of HBsAg, anti-HBs, and anti-HBc among the entire population surveyed in 2023 were 2.25% (95%CI:1.64–2.87), 46.21% (95%CI:44.05–48.38), and 25.17% (95%CI:23.46–26.88), respectively. Among the 1,177 individuals aged 1–29 years, only 5 (0.28%) were detected positive for HBsAg. Notably, none of the children aged 1–9 years were detected. The individuals who tested positive for HBsAg were predominantly distributed among those aged 30 years and older (t = 4.55, p < 0.05). The peak prevalence of HBsAg was observed in individuals aged 40–49 years (5.63%) and 30–39 years (3.11%). Similarly to that of HBsAg, anti-HBc positivity was predominantly present in individuals aged ≥ 30 years compared to those aged 1–29 years (t = 7.09, p < 0.001). Furthermore, the prevalence of anti-HBc exhibited a gradually increasing trend with age in those aged 30 years and older (Table 2). The prevalence of anti-HBs was highest in children aged 1–4 years (78.57%) and then decreased to 36.50% and 38.53% in children aged 10–14 and 15–19 years, respectively. Subsequently, there was a slight increase in the prevalence of anti-HBs in the age groups of 20–29 and 30–39 years (51.11% and 59.82%, respectively), which then declined with increasing age. The prevalence of HBsAg, anti-HBs, and anti-HBc was comparable between males and females. The prevalence of HBsAg was found to be slightly lower in urban areas compared to rural areas. In contrast, the prevalence of anti-HBs and anti-HBc was slightly higher in urban areas. However, these differences were not statistically significant (all p > 0.05). The highest prevalence of HBsAg was identified in public service workers (3.85%), followed by workers (3.53%) and farmers (3.46%) (Table 3). Table 3Prevalence of HBV serological markers by gender, occupation, and residential area in Shandong Province, 2023Sample testedHBsAgAnti-HBsAnti-HBcSeroprevalence(% (95% CI))P valueSeroprevalence(% (95% CI))P valueSeroprevalence(% (95% CI))P value Gender Male22592.43 (1.49–3.37)Reference45.72 (42.50-48.93)Reference25.15 (22.64–27.66)ReferenceFemale27402.07 (1.28–2.86)0.39046.72 (43.83–49.62)0.64225.19 (22.89–27.49)0.933 Occupation Farmer22273.46 (2.25–4.66)Reference35.92 (33.26–38.58)Reference36.38 (33.73–39.04)ReferenceWorker4473.53 (0.96–6.10)0.04051.18 (44.26–58.10)0.52524.55 (18.55–30.55)0.599Cadre2672.47 (0.18–4.76)0.11455.59 (46.88–64.31)0.04024.52 (18.06–30.98)0.884Student7040.03 (0.00-0.10)0.00345.36 (40.06–50.66)0.3364.98 (2.92–7.04)0.004Medical staff952.30 (0.00-6.44)0.19476.19 (65.34–87.04)< 0.00117.54 (7.53–27.55)0.040Public service worker1643.85 (0.00-7.91)0.00242.26 (31.00-53.52)0.01919.99 (11.98–28.01)0.237Retiree2711.64 (0.00-3.82)0.84139.29 (31.45–47.13)0.01443.29 (35.23–51.35)< 0.001Household and unemployed personnel4171.87 (0.53–3.20)0.62642.64 (34.69–50.59)0.03334.41 (27.17–41.65)0.032Others2091.89 (0.09–3.68)0.65951.66 (38.81–64.51)0.66628.03 (21.70-34.36)0.073 Residential area Urban24992.04 (1.42–2.66)Reference50.44 (44.97–55.87)Reference27.38 (25.06–29.72)ReferenceRural25002.38 (1.88–2.88)0.35143.62 (37.84–49.40)0.21223.81 (22.74–24.89)0.056 Geographic location Western Shandong15003.00 (2.02–3.97)Reference43.96 (41.55–46.37)Reference25.05 (22.69–27.42)ReferenceCentral Shandong15001.88 (0.96–2.81)0.06350.01 (43.75–56.28)0.26924.92 (21.05–28.70.926Eastern Shandong19992.17 (1.63–2.72)0.64645.30 (39.24–51.35)0.69725.32 (23.72–26.91)0.856 Prevalence of HBV serological markers by gender, occupation, and residential area in Shandong Province, 2023 Comparison of HBV serologic markers prevalence in 2006, 2014, and 2023 We compared the findings of the 2023 survey with those from previous surveys conducted in 2006 and 2014 (both covering individuals aged 1–59 years). The HBsAg prevalence among children aged 1–14 years declined by 85% during 2006–2014 (from 1.36 to 0.21%) and 86% during 2014–2023 (from 0.21 to 0.03%), including a 100% reduction among children aged 1–4 years and 83% among children aged 5–14 years during 2014–2023. Additionally, a slight decline (from 3.01 to 2.96%) was also observed among individuals aged 15–59 years during 2014–2023. The prevalence of anti-HBs increased by 9% (from 72.14 to 78.57%) among children aged 1–4 years, and by 17% (from 40.04 to 46.88%) among individuals aged 15–59 years during 2006–2023. Conversely, a decline was observed among individuals aged 5–14 years, with a reduction from 66.71 to 48.38%. During 2006–2014, the prevalence of anti-HBc among individuals aged 1–4, 5–14, and 15–59 years exhibited a decline from 2.18 to 1.35%, from 5.18 to 2.03%, and from 28.46 to 27.26%, respectively. However, there was a rebound from 1.35 to 7.87% and from 2.03 to 3.43% among children aged 1–4 and 5–14 years, respectively, during 2014–2023 (Fig. 2). Comparison of the 2023 survey with the 2006 and 2014 results: (A) Comparison of HBsAg prevalence, (B) Comparison of anti-HBs prevalence, (C) Comparison of anti-HBc prevalence. Note: HBsAg, hepatitis B virus surface antigen; Anti-HBs, antibody against hepatitis B surface antigen; Anti-HBc, antibody against hepatitis B core antigen Discussion The findings of the four sero-epidemiological surveys conducted among the community population of Shandong Province revealed a decline in the prevalence of HBsAg, from 6.40% in 1992 (1–59 years) [12] to 3.39% in 2006 (1–59 years) [10], to 2.49% in 2014 (1–59 years) [10], and to 2.25% (the entire population aged over 1 year) in 2023. Our findings highlight the fact that the province remains an area of intermediate endemicity of HBV infection, yet it is undergoing a gradual transition towards a low-prevalence status (< 2%). In comparison to the prevalence of HBsAg among individuals younger than 30 years in the pre-vaccine era of 1992, the 2023 survey revealed a marked reduction in this metric, falling to a prevalence of only 0.28%. Of note, the prevalence among children aged 1–14 years had declined from 8% in 1992 [12], to 1.36% in 2006 [10], to 0.21% in 2014 [10], and further to less than 0.1% in 2023. If the province is taken as a unit, this represents a great advance towards the WHO’s goal of eliminating viral hepatitis as a public health threat by 2030. A model estimation indicates that the HBsAg positivity rate among children aged < 5 years in China is anticipated to fall below 0.1% by 2025 [16]. The observed decline in HBsAg prevalence should be attributed primarily to the beneficial impact of universal childhood vaccination policies beginning in 1992 and having covered all the population under 30 years of age by 2023. Additionally, the program for integrating the prevention of MTCT of HIV, syphilis, and HBV has had a positive impact since 2011, which provided HBsAg screening for pregnant women and free HBIG for infants born to all HBsAg-positive mothers. The Chinese government plans to achieve the goal of eliminating MTCT of the three diseases by 2025, with one of the aims of reducing the rate of HBV transmission to less than 1%. A national evaluation and validation of the Shandong Province’s elimination program is scheduled to be completed in the second half of 2024. In the 2023 survey, the higher prevalence of HBsAg was present in individuals aged ≥ 30 years, similar to the results of other seroepideniology studies conducted in China [17, 18]. Subsequent analysis indicated that the peak prevalence of HBsAg was seen in the population aged 30–49 years, consistent with the results of the 2020 survey in Beijing [19]. With the improvement of routine hepatitis B immunization, the shift in the age of HBV infection, and the improvement of socio-economic levels, it is becoming increasingly evident that an emphasis on hepatitis B immunization for populations beyond eligible children is also essential for accelerating hepatitis B elimination. The administration of HepB to healthy adults has been shown to be good at inducing the production of protective antibodies and providing a long-lasting immune memory [20–23]. However, in recent years, only a limited number of pilot areas in Shandong Province have implemented a free HepB policy for certain high-risk adults, whereas the province as a whole still adopts a voluntary, self-paid model of HepB immunization for adults. The deficiencies in this strategy, coupled with other factors, have resulted in suboptimal HepB coverage in the province, especially in rural areas [24]. Thus, HepB immunization for susceptible adults should be intensified so as to reduce the incidence of hepatitis B in adults and the whole population. Consistent with previous findings [9, 17, 18], the results of our study in 2023 indicated that the prevalence of anti-HBs was highest among children aged 1–4 years, which strongly demonstrates the efficacy of immunization, as well as the outcome of treatment with HBIG in newborns born to HBsAg-positive mothers. Additionally, we observed a subsequent decline in anti-HBs prevalence with increasing age among those under 20, followed by a rebound in the 20–39 age groups. The observed increase in the 20–29 age group might be primarily attributed to the implementation of a booster dose of HepB to college freshmen with negative or weakly positive serological results [25]. The rise in the 30–39 age group was likely the result of a combination of factors, including vaccination and an increase in natural HBV infection. Currently, it is generally not recommended to provide booster immunizations for immunologically completed individuals who have received a full primary series due to the presence of immune memory [26, 27]. Nevertheless, some researchers hold the view that the booster immunization should be administered when anti-HBs levels decreased < 10 mU/ml, as this may result in the loss of immune memory and an increased difficulty in stimulating the memory response [28, 29]. This recommendation is also extended to immunocompromised individuals (such as those infected with HIV and individuals with chronic renal failure) who may be unable to generate a sufficient primary or secondary immune response [30]. In the population of healthcare professionals, the booster dose can be made mandatory for those with low antibody titers who are exposed to the risk of accidents with high doses of the agent, thereby rendering their immune system insufficient for an immediate and protective immune response [31]. Further studies are needed to offer insights into the optimal vaccination strategies for ensuring durable protection against HBV. As expected, the 2023 survey revealed that the prevalence of anti-HBc was markedly higher in individuals aged ≥ 30 years than in those aged 1–29 years, which was in accordance with the HBsAg findings of this study. Notably, children aged 1–4 years showed a higher prevalence of anti-HBc compared to that in 2014. In light of the fact that none of these children had HBsAg positivity, it is speculated that the elevated prevalence of anti-HBc might be attributable to vertical transmissions, potentially occurring through the placental barrier or as a consequence of recovery from an HBV infection that occurred at or around the time of birth (intrapartum or peripartum). Given the high success rate of immunoprophylaxis (> 95%) in reducing the incidence of HBV transmission among newborns, further investigation of maternal HBV serological markers is essential to elucidate the underlying cause of the observed anti-HBc prevalence [32]. Also, the relatively small sample size of this age group in the 2023 survey might lead to potential biases in the study. Additionally, the presence of anti-HBc in younger children might also be attributed to self-limiting infections resulting from household exposure to HBV, despite the high neonatal HepB coverage rate of over 95% in the province. The study found that the prevalence of HBsAg, anti-HBs, and anti-HBc among different occupational groups in 2023 varied considerably, with relatively high HBsAg prevalence observed in public service workers, farmers, and workers. This finding aligns with results from prior studies conducted in the province and other regions [10, 19, 34]. The high prevalence in these groups was likely due to a combination of factors, including frequent interpersonal contact, limited knowledge about HBV infection and prevention, and low awareness of proactive HepB vaccination. It is recommended to publicize and popularize the knowledge of hepatitis B for these occupational groups. Concurrently, efforts should be made to elevate the coverage of HepB for them. As a country with the greatest burden of HBV infection worldwide, China will play a pivotal role in the global eradication of hepatitis B by 2030 [35]. However, the current situation is such that there are still large gaps in achieving the goals of reducing HBV mortality and elevating the coverage of diagnosis and treatment [36]. The current high prevalence of HBsAg in older adults represents a substantial risk factor for HBV transmission and chronic complications. Furthermore, the majority of chronic HBV-infected individuals were unaware of their HBV infection status, with a previous study showing that more than 80% of adults with HBV infection were unable to receive treatment due to a lack of awareness about their illness [37]. A delayed diagnosis can result in a delayed detection of cirrhosis, liver failure, and hepatocellular carcinoma due to the asymptomatic nature of these conditions until the onset of end-stage liver disease [38]. Consequently, the implementation of optimal hepatitis B screening and management strategies, along with the early initiation of treatment, will be a critical step towards the goal of eliminating hepatitis B in China. The 2023 survey was a multi-stage sampling survey with a sample size of 4999. The obtained results were able to provide a reasonable estimate of the prevalence of HBV serum markers in the population of Shandong Province, and provide baseline data for further efforts to eliminate hepatitis B in the province. However, some limitations of the study should also be taken into consideration. Firstly, the sampling population for the 2023 survey was derived from the serosurvey of anti-SARS-CoV-2 antibodies. In comparison to the surveys conducted in 2006 and 2014 [10, 11], the sampling method employed in this survey had a relatively smaller proportion of participants in the younger age group, particularly those aged 1–4 years. This may have an impact on the stability of the results for this cohort of participants. Secondly, the testing methods used in the 2023 survey differed from those used in 2006 and 2014, potentially resulting in certain observational biases in the prevalence of HBV serological markers. The 2006 and 2014 surveys utilized enzyme-linked immunosorbent assay (ELISA), whereas the 2023 survey used CMIA assay. The CMIA assay represents the pinnacle of technological advancement, offering the benefits of high sensitivity and specificity [39, 40]. Hence, it may be more effective than ELISA methods in detecting positive serologic indicators of HBV. However, specimens with indeterminate results in the 2006 and 2014 surveys were also reconfirmed through the use of the CMIA assay with Abbott reagent [10]. Consequently, we believe that the detection results of this survey were still sufficiently comparable to those of 2014 and 2016. Lastly, the 2023 survey failed to gather additional detailed information from the study participants, including the history of hepatitis B immunization and other HBV infection risk factors, thus preventing the conduct of a more comprehensive analysis. In conclusion, our study demonstrated that 30 years after the implementation of the neonatal vaccination program, Shandong Province has achieved substantial success in controlling the prevalence of HBV infection among young people. However, the prevalence of HBV infection remains relatively high among persons older than 30 years. In order to improve the efficacy of the ongoing efforts to combat hepatitis B, more attention should be paid to the implementation of comprehensive interventions for HBV-susceptible adults and the improvement of screening and standardized treatment rates for chronically HBV-infected individuals. Such actions have the potential to facilitate the province and the country as a whole in achieving the WHO’s target of hepatitis B elimination by 2030. Acknowledgements We thank all the relevant health workers who took part in the collection of samples from CDCs of Shizhong, Huangdao, Linzi, Laishan, Qingzhou, Liangshan, Rongcheng, Lanling, Yucheng and Mudan in the study. Author contributions Li Zhang contributed to study concept. Bingyu Yan, Xiaomeng Zhang contributed to initial drafting of the manuscript. Bingyu Yan, Jngjing Lv, Yi Feng, Xin Meng, Xiaojuan Lin, Yan Zhang, Suting Wang, Feng Ji, Meng Chen, Xinyu Yuan, and Zexin Tao contributed to the collection of data and blood sample. Bingyu Yan and Xiaomeng Zhang contributed to data analyse. Li Zhang contributed to critical review and revision of the article.All authors have reviewed the manuscript. Funding This work was supported by grants from the Taishan Scholar Program of Shandong Province, China (No. tstp20221164). Data availability Data used and analyzed during this study are provided in full within the present manuscript. Declarations Ethics approval and consent to participate The survey was approved by the Ethics Committee of the China CDC. The informed consent was obtained from all participants, or their parents or legal guardians if the participants were under the age of 18. The use of the remaining samples to test for serologic indicators of hepatitis B was approved by the Shandong CDC Ethics Committee (SDJK-2023-012-01). Consent for publication All participants consented to the publication of this manuscript. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Data used and analyzed during this study are provided in full within the present manuscript.